CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients. By Rebecca Robbins ...

Starting July 1, Zepbound will no longer be preferred on CVS Caremark’s standard formulary, while Wegovy and other anti-obesity medicines will be, according to the company. The change means that ...

CVS’s drug-benefits unit, known as Caremark, earlier this month negotiated a deal to make Novo’s Wegovy more widely available to its customers — knocking Eli Lilly & Co.’s Zepbound off its ...

This month, CVS Caremark announced that it had also signed a deal to make Novo Nordisk’s Wegovy its preferred GLP-1RA starting in July, which concurrently deprioritised coverage for Zepbound.

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Zepbound will be excluded. This could complicate access to a drug that many patients cannot afford to pay for on their own. The formulary is maintained by CVS Health’s pharmacy benefits ...

Earlier this month, CVS Caremark announced that it will now cover Wegovy under its pharmacy benefit plans — but it will no longer cover Zepbound. A study published in the New England Journal of ...

Many patients may have to switch obesity drugs now that CVS Caremark opted to stop offering tirzepatide (Zepbound) in favor of semaglutide (Wegovy), despite the latter yielding less weight loss.